Aktiv Pharma Group wins contract valued at up to $220 million to supply life-saving emergency autoinjectors to the Strategic National Stockpile
Aktiv Pharma Group is awarded a contract by the U.S. Department of Health and Human Services to supply pralidoxime chloride autoinjectors, a nerve agent antidote, to the Strategic National Stockpile. The contract is currently valued at over $45 million and could total up to $220 million over seven years with the exercise of contract options.
BROOMFIELD, Colo., Oct. 5, 2022 /PRNewswire-PRWeb/ -- Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project BioShield Act, Aktiv will supply emergency autoinjectors containing pralidoxime chloride (2-PAM) to the CHEMPACK program, targeting proposed indications related to organophosphate poisoning including nerve agents. The total value of the contract, including options to continue supplying the product until 2029, is up to $220 million. "We are humbled by the opportunity to support the U.S. Government to enhance its readiness and preparedness to protect the U.S. civilian population and provide peace-of-mind to the emergency first responders if they have to use these products," said the company founder and CEO, Amir Genosar.
The ARAI autoinjector has been developed by Aktiv with the support of the Department of Defense (DoD) and BARDA as a next generation autoinjector platform to address the shortfalls of previous autoinjectors, by improving usability, reliability, robustness, and drug stability. ARAI is a versatile platform that can deliver up to 5 ml dose volumes, perform simultaneous injections of multiple, separately stored drug formulations, and automatically reconstitute drugs formulated in dry form. Aktiv is currently expanding the ARAI platform to include a consumer market autoinjector for biopharmaceuticals that will feature the same reliability, robustness, and usability benefits in a smaller form factor and with added data connectivity.
Aktiv is leveraging its superior autoinjector technology to advance the strongest emergency treatment pipeline in the industry, which currently includes atropine, pralidoxime chloride (2-PAM), atropine/2-PAM dual-injection, scopolamine, and tranexamic acid (TXA). Aktiv is also collaborating with another pharmaceutical company to develop a reconstitution autoinjector for a long-acting formulation of naloxone.
About Aktiv
Aktiv is a vertically integrated specialty pharmaceutical company with combination product contract development and manufacturing organization (CDMO) capabilities, developing, manufacturing, and commercializing sterile injectable products in a portfolio of proprietary, value-added, glass-free prefilled delivery systems. Aktiv's has unique combination product competencies, specifically targeting biopharmaceuticals. The company's facilities in Colorado include device development, chemistry, manufacturing and controls (CMC), and manufacturing equipment labs, assembly rooms operated under current Good Manufacturing Practice (cGMP), and sterile fill-finish suites. Aktiv can be reached at https://aktivpharmagroup.com/contact.
Media Contact
Slavek Sloniowski, Aktiv Pharma Group, 1 7208288088, [email protected]
SOURCE Aktiv Pharma Group
Share this article